Thalidomide – Targeted Therapy

Thalidomide is an immunomodulatory agent with potent antitumor, antiangiogenic, and anti-inflammatory properties. Despite its complex historical reputation, the drug is now a standard of care for several severe oncological and immunological conditions.

The mechanism of action of thalidomide is multifaceted. It inhibits the production of tumor necrosis factor-alpha (TNF-α), alters cytokine balance, and blocks angiogenesis (the formation of new blood vessels), which deprives the tumor of nutrients. In the treatment of multiple myeloma, thalidomide directly inhibits the growth of cancer cells and disrupts their interaction with the bone marrow microenvironment. Furthermore, it stimulates T-lymphocytes and natural killer (NK) cells, enhancing the body's own immune response against the tumor.

The drug is administered orally in capsule form. Due to the high risk of serious adverse effects, its prescription is strictly controlled through specialized risk management programs.

Wikipedia page
Thalidomide

Indications

Thalidomide is indicated for the treatment of adult patients in the following clinical cases:

  • Multiple Myeloma: in combination with dexamethasone or melphalan for patients with newly diagnosed disease.
  • Erythema Nodosum Leprosum (ENL): for the acute treatment of moderate to severe cutaneous manifestations and as maintenance therapy to prevent relapse.

Dosage and administration

Thalidomide dosing is tailored individually based on the clinical indication and patient tolerance.

  • For Multiple Myeloma: the standard dose is 200 mg once daily, taken orally.
  • For ENL: the starting dose ranges from 100 to 300 mg daily, followed by a gradual reduction to a maintenance dose.
  • Administration Rules: the drug is recommended to be taken at bedtime to minimize the impact of its sedative effects. Capsules should be swallowed whole.
  • Monitoring: regular monitoring of peripheral nerve function and blood coagulation parameters is mandatory during treatment.

The use of thalidomide is subject to stringent restrictions:

  • Pregnancy: the drug is extremely teratogenic (causing severe birth defects). It is strictly contraindicated in pregnant women or those planning pregnancy.
  • Breastfeeding: safety has not been established; breastfeeding is prohibited.
  • Hypersensitivity: allergic reactions to thalidomide or its components.
  • Severe Neuropathy: pre-existing severe peripheral nerve damage.
  • Pediatric Use: safety and efficacy in children and adolescents under 18 years of age have not been established.

Thalidomide therapy requires constant medical supervision due to the risk of the following reactions:

  • Teratogenicity: risk of phocomelia and other fetal defects (strict contraception is mandatory).
  • Nervous System: peripheral neuropathy (numbness, tingling, pain in extremities), somnolence, and dizziness.
  • Thromboembolism: increased risk of deep vein thrombosis and pulmonary embolism (anticoagulants are often required).
  • Gastrointestinal: constipation (very common) and dry mouth.
  • Dermatologic: rash, dry skin, and rarely, Stevens-Johnson syndrome.
  • General: bradycardia (slow heart rate) and edema.

Frequently Asked Questions

Thalidomide is an immunomodulatory agent with antineoplastic activity. It works through a complex mechanism: it blocks the growth of blood vessels that nourish the tumor (anti-angiogenic effect), stimulates immune cells (T-cells and NK-cells) to attack the cancer, and directly inhibits the division of myeloma cells within the bone marrow.
In modern medicine, thalidomide is most commonly used in combination with melphalan and prednisone for the treatment of newly diagnosed multiple myeloma in patients over 65 years of age. It is also used to treat severe skin manifestations of erythema nodosum leprosum (ENL).
Thalidomide is extremely teratogenic; even a single dose taken during pregnancy can cause severe birth defects. Consequently, the drug is only dispensed through a strict risk management program. Both women and men must use highly effective contraception and undergo regular pregnancy testing during therapy.
The substance frequently causes peripheral neuropathy (nerve damage), presenting as numbness, tingling, or pain in the hands and feet. Thalidomide also has a significant sedative effect, causing drowsiness and slowed reactions; therefore, it is typically recommended to be taken at bedtime.
Taking thalidomide, especially in combination with chemotherapy or dexamethasone, significantly increases the risk of blood clots (venous thromboembolism). Patients are often prescribed thromboprophylaxis with aspirin or heparin. Additionally, bradycardia (slow heart rate) may occur, requiring heart rate monitoring.

List of medicines by active substance Thalidomide

-13%
Thalix-100 100 mg Fresenius Kabi
View
Fresenius Kabi

Thalix-100

Thalidomide
100 mg 30 capsules
1538₴ 1758₴
✅ All products loaded (1)

Contact us

Choose a convenient way to contact

We work daily from 9:00 to 20:00